drugset / Trial / NCT03930953
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.
Timeline
- Start
- 2019-05-20
- Primary completion
- 2027-04-07
- Completion
- 2028-02-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Golcadomide | Other / unclassified | — | Oral |
| Subject | Obinutuzumab | Monoclonal antibody | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |
| Subject | Tafasitamab | Monoclonal antibody | — | — |
| Subject | Valemetostat | Small molecule | — | — |